logo-loader
viewMatinas BioPharma

Full interview: Matinas BioPharma says Vascepa label expansion is 'ideal for the [Omega 3] class to kick off'

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive he's pleased the FDA is giving 'an early holiday gift' in the form of its approval for Amarin Corporation's (NASDAQ:AMRN) fish oil-derived drug Vascepa, now approved to prevent heart attacks and strokes in people who are at high cardiovascular risk.

Jabbour says the Vascepa label expansion is 'ideal for the [Omega 3] class to kick off,' and beneficial to patients, giving them greater access to a drug that can fight cardiovascular disease.

Quick facts: Matinas BioPharma

Price: 1.03 USD

NYSE:MTNB
Market: NYSE
Market Cap: $200.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Standard Uranium shares details of their project as they...

Standard Uranium (CVE: STND) President and CEO Jon Bey sat down with Steve Darling from Proactive Vancouver to discuss details about uranium exploration company that plan to take public very soon.  Bey telling Proactive about their project in the Athabasca Basin and also abut their...

12 hours, 21 minutes ago

2 min read